Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17104387 | 1.00 | GRIN1 (0.45) | GRIN1GRIN2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6561158 | 0.99 | GRIN1 (0.44) | GRIN1GRIN2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6562366 | 0.89 | GRIN1 (0.47) | GRIN1GRIN2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7897054 | 0.89 | EPHX2 (0.44) | GRIN1GRIN2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7898530 | 0.89 | NPY4R (0.47) | SMN1; SMN2CPB2 | |
| SCHEMBL7898542 | 0.87 | NPY4R (0.47) | GRIN1GRIN2ASMN1; SMN2 | |
| SCHEMBL19165692 | 0.84 | C3AR1 (0.36) | GRIN1GRIN2ASMN1; SMN2EPHX2 | |
| SCHEMBL10277291 | 0.82 | EPHX2 (0.47) | GRIN1GRIN2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL29421098 | 0.82 | MEN1 (0.44) | SMN1; SMN2EPHX2 | |
| SCHEMBL10650846 | 0.82 | MEN1 (0.44) | SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040062773-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES INC. | 2004-04-01 | — | — | US | claimed |
| EP-0784469-B1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 2004-03-24 | — | — | EP | claimed |
| US-6610329-B2 | Using acylated amino acid as carrier | EMISPHERE TECHNOLOGIES INC. | 2003-08-26 | — | — | US | claimed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | claimed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0784469-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | claimed |
| US-10632171-B2 | Melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES INC (US) | 2019-07-18 | — | — | US | disclosed |
| US-10179804-B2 | Melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160318977-A1 | Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES INC (US) | 2016-11-03 | — | — | US | disclosed |
| US-9458201-B2 | Melanocortin receptor-specific heptapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-5629020-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0758843-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | Emisphere Technologies, Inc. (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1996021464-A9 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996021464-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1995028838-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020001591-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | GRIN1 2464/4885GRIN2A 2146/4885CHRNB2 2707/4885 |
| US-20040062773-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | GRIN1 2464/4885GRIN2A 2146/4885CHRNB2 2707/4885 |
| US-10179804-B2 | Melanocortin receptor-specific peptides | MC1R, MC3R, MC5R | GRIN1 819/4885GRIN2A 1037/4885CHRNB2 278/4885 |
| US-20190216887-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC4R | GRIN1 730/4885GRIN2A 789/4885CHRNB2 194/4885 |
| US-20160318977-A1 | Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC5R | GRIN1 819/4885GRIN2A 1037/4885CHRNB2 278/4885 |
| US-10632171-B2 | Melanocortin receptor-specific peptides | MC1R, MC3R, MC4R | GRIN1 730/4885GRIN2A 789/4885CHRNB2 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.